ISRG Intuitive Surgical NASDAQ +2.48% $488.15 06 Feb 2026: AI stocks view

ISRG stock closed at $488.15 on 06 Feb 2026, up +2.48% as investors reacted to continued da Vinci system demand and fresh institutional buying. Trading on the NASDAQ in the United States, Intuitive Surgical reported solid margin metrics and healthy cash on the balance sheet, keeping growth debates active. We assess why the move happened, how valuation stacks up with a PE of 62.18, and what that means for AI-focused portfolios and surgical robotics exposure.

ISRG stock: Today’s price action and volume drivers

ISRG stock finished the market session at $488.15, trading between $480.07 and $491.65 with volume of 2,518,458.00 shares versus an average of 1,905,611.00. Institutional buying and recent insider filings lifted sentiment; marketbeat.com flagged purchases and filings that tracked higher flows into the name source.

The uptick followed a broader healthcare rebound and pockets of buying tied to da Vinci 5 adoption commentary. Short-term momentum indicators (RSI 65.69) and MACD show modest bullishness, but the 50-day average ($552.16) still sits above spot price, signaling resistance ahead.

ISRG stock: Fundamentals, margins and cash profile

Intuitive Surgical reports trailing EPS of 7.85 and a trailing PE near 62.18, reflecting premium pricing for growth expectations. The company has strong profitability: net margin roughly 28.38%, operating margin near 29.27%, and free cash flow per share of 6.40, supporting ongoing R&D and system installs.

Balance-sheet strength is notable: cash per share 13.83 and a current ratio of 4.73, with virtually no debt. These metrics anchor valuation but also justify a higher multiple only if revenue growth sustains.

ISRG stock: Technicals and trading signals for AI stocks investors

Technicals show mixed reads for ISRG stock. Momentum is positive with MACD histogram 0.11 and ROC 6.01%, while ADX 22.53 indicates a nascent trend rather than a strong directional move. Bollinger ranges put the upper band near 590.15, suggesting room to re-test higher levels if demand returns.

For AI stocks strategies, ISRG’s relative outperformance depends on da Vinci 5 adoption and digital service uptake. Traders should watch the 50-day ($552.16) and 200-day ($516.38) moving averages for trend confirmation.

ISRG stock: Risks, near-term catalysts and analyst positioning

Key risks include premium valuation, slower hospital procurement cycles, and competitive moves in robotic systems and diagnostics. Insiders sold shares recently, and several funds adjusted positions by early February, which adds a short-term supply consideration.

On the catalyst side, Q1 and the April earnings announcement (2026-04-21) will be pivotal for system shipments, attach rates, and recurring revenue guidance. Wall Street price targets vary with an average near $620.41, showing upside but also dispersion across analysts source.

Meyka AI grade and valuation read on ISRG stock

Meyka AI rates ISRG with a score out of 100: 78.55 (B+, BUY). This grade factors in S&P 500 comparison, healthcare sector performance, industry peers, financial growth, key metrics, analyst consensus, and forecast durability. The grade highlights strong cash flow, high margins, and a robust install base.

This grade is informational only and not guaranteed. We are not financial advisors. Investors should weigh valuation (price/sales 17.21, price/book 10.23) against growth before adding exposure.

ISRG stock forecast and model outlook for AI stocks portfolios

Meyka AI’s forecast model projects a 1-year target of $605.93, a quarterly target near $508.28, and a monthly target near $504.41. Versus the current price of $488.15, the 1-year projection implies an upside of 24.13%, and the quarterly projection implies 4.13% upside. Forecasts are model-based projections and not guarantees.

These modeled levels assume continued adoption of advanced systems, steady instrument attach growth, and stable hospital capital spending. Revisions would follow updated earnings on 2026-04-21.

Final Thoughts

ISRG stock closed the market at $488.15 on 06 Feb 2026 after a +2.48% daily move driven by institutional buying and steady surgical demand. Intuitive Surgical remains a premium healthcare growth name with a trailing PE of 62.18, strong margins and no net debt. Our Meyka AI grade of 78.55 (B+, BUY) balances that quality against high valuation. For AI stocks allocations, ISRG offers exposure to procedural automation and data-enabled surgery, but investors must accept valuation sensitivity and execution risk. Meyka AI’s forecast model projects $605.93 in 12 months, implying about 24.13% upside from today’s price; forecasts are model-based and not guarantees. Watch upcoming earnings (2026-04-21), 50/200-day moving averages, and attach-rate commentary for re-rating triggers. For deeper metrics and an updated trade screen, see our Meyka ISRG page and track official filings and analyst notes.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.